Global pharmaceutical company Merck (NYSE:MRK) met Wall Street’s revenue expectations in Q2 CY2025, but sales fell by 1.9% ...

Merck & Co on Tuesday announced job and cost cuts that it said will save $3 billion a year, after it posted lower ...

Along with its financial results for the second quarter of 2025, Merck revealed a restructuring plan to save $3 billion by ...

The restructuring includes the elimination of certain roles and a reduction in the company’s global real estate footprint.

Merck has launched a sweeping cost-cutting effort designed to save $3 billion annually by the end of 2027, the company said ...

Facing an end to Keytruda's market exclusivity, the company will cut $3 billion in costs that it plans to redeploy in support ...

CEO Rob Davis referred to the cost reduction program as a “reallocation” rather than a cut, with the savings to be reinvested ...

Merck said on Tuesday it was extending its pause on Gardasil shipments to China until at least the end of 2025 due to persistent weakness in demand for the blockbuster human papillomavirus vaccine, ...

Analysts estimate that Merck & Co will report an earnings per share (EPS) of $2.01. Investors in Merck & Co are eagerly ...

Merck & Co. is slashing $3 billion from its annual spending as it braces for off-brand competition to its cancer drug ...